This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dyax Corp. Q2 2010 Earnings Call Transcript

I will now turn the call over to Gustav Christensen, our President and CEO. Gustav?

Gustav Christensen

Thank you, Nicole. Good morning and thank you for joining Dyax’s second quarter earnings conference call. Joining me today are George Migausky, EVP and Chief Financial Officer; Ivana Magovcevic-Liebisch, EVP Corporate Development and General Counsel; and Bill Pullman, EVP and Chief Development Officer.

We are pleased with the positive progress made during our first full quarter of US commercial launch of KALBITOR. And we’ll turn to those updates and other company news shortly. However, before doing so, George will go through the financial highlights of the second quarter. George?

George Migausky

Thank you, Gustav, and good morning to all. This morning’s press release contains the full financial results for the second quarter. So let me begin by highlighting some of the noteworthy financial events of the quarter. This was the first full quarter of the US commercial launch of KALBITOR and cumulative net sales have now reached $3.2 million, which reflects a 55% increase over Q1. Operating costs in the first half of 2010 were reduced by 25% to $32.9 million despite adding all of the new KALBITOR commercial launch expenses.

In the second quarter of 2010, our net operating cash burn was reduced to $11.4 million and our cash balance at June 30, 2010, which includes a cash equivalents and investments totaled $94.4 million. As reported earlier today, for the second quarter of 2010, total revenues increased to $15.1 million as compared to $4.8 million in the same quarter last year. And for the six-month period, revenues increased to $35.2 million from $10.8 million in the prior year. The higher revenue in the second quarter was primarily due to two factors. First, net product sales of KALBITOR, which were 1.9 million and second, $9.8 million of revenue recognized from the sale of our rights to royalties and other payments related to the commercialization of Xyntha by Pfizer.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs